Immune surveillance is the research framework for how the immune system detects and responds to abnormal cells, including virus-infected cells and tumour cells. It is not a personal test of cancer protection. The clearest distinction is between recognising a target and controlling it. The National Cancer Institute (NCI) defines natural killer (NK) cells as a type of immune cell with granules containing enzymes that can kill virus-infected cells and tumour cells. That describes a capacity. It does not mean every abnormal cell is found, or that a found cell is always eliminated.
Recognition is a step, not a verdict
Recognition happens when an immune cell encounters a target and receives signals that make it respond. For NK cells, the NCI definition gives a concrete example: they carry granules with enzymes that can kill virus-infected and tumour cells. In tumour immune surveillance, the question is not only whether such a cell can recognise a tumour cell in principle, but whether the response works in the tissue where the tumour is growing. This is an explanatory distinction, not a claim that recognition always leads to control.
Tumours can blunt the response
The NCI's overview of immunotherapy for cancer describes ways tumours escape immune attack. That matters because escape is the practical gap between surveillance and protection: an abnormal cell can be recognised, or be recognisable, while the immune response is still limited by the tumour's local defences. A study titled 'Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity' supports the idea that NK cells can become functionally impaired after entering tumour tissue in an experimental model. The work is about local functional limitation and exhaustion in that model. It does not establish that the same pattern happens in every human cancer, nor does it predict an individual's outcome.
Immunotherapy is a category, not a guarantee
The NCI lists immunotherapy as a cancer treatment category and describes tumour escape mechanisms. Those are broad treatment categories, not a verdict on a particular product. A finding that NK cells can kill tumour cells, or that they become impaired in a tumour model, is not the same as evidence that an NK-cell infusion benefits a patient. A cell assay is not patient benefit; a trial design is not a result. Likewise, a treatment category on an official overview does not automatically apply to every NK-based approach, every cancer type or every country.
Three boundaries worth keeping straight
Swipe or scroll to read the full table →
| Distinction | What it helps clarify |
|---|---|
| Recognition vs control | The NCI describes NK cells as able to kill virus-infected and tumour cells, and the NCI's immunotherapy overview describes tumour escape mechanisms. Recognition alone is not proof of individual protection. |
| Experimental model vs human disease | The NK-cell study supports research on local functional impairment and exhaustion in a tumour environment. It is not a measurement of every patient's immune response. |
| Treatment category vs specific product | The NCI's immunotherapy overview describes broad treatment categories and escape mechanisms. It does not establish that a particular NK-cell product is effective or appropriate in a given case. |
What the framework is good for
The term 'tumour immune surveillance' is most useful as a way to organise questions: What is being recognised? By which immune cell? Is the response working in the tumour environment, which includes the cells and conditions around a tumour? And what kind of evidence is being described—a laboratory finding, an experimental model, a trial design or a clinical result? The framework helps explain why immune recognition and immune control are not the same thing. It does not promise that an individual will be protected from cancer, and it does not turn a cell assay into a treatment outcome.
This is general educational information, not medical advice.